Track topics on Twitter Track topics that are important to you
Hutchison China MediTech (Chi-Med) filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. In September 2018, Chi-M...
Innovent Biologics and Hutchison China MediTech agreed to work together to advance Elunate, or fruquintinib, in combination w -More-
The first China-discovered treatment for cancer is now launched. Hutchison China MediTech (Chi-Med) and Lilly have begun China marketing of Elunate (fruquintinib), a VEGF-inhibitor approved to treat m...
Hutchison China MediTech (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate) with the initiation of product sales in China. As quoted in the press release:...
Hutchison China MediTech (Chi-Med) has started four collaborations that will test its VEGFR inhibitors (surufatinib or fruquintinib) in combination with PD-1 checkpoint inhibitors from other biopharma...
Hutchison China MediTech (Chi-Med) has reported positive data from interim analysis of the pivotal Phase III SANET-ep clinical trial of...Read More... The post Chi-Med to end surufatinib’s Phase III...
One-third of people living with HIV in China are still unaware of their status, so we sought to better understand HIV testing in the general hospital setting in China.
Tobacco mosaic virus (TMV) is widespread in China and causes considerable economic losses to tobacco production. The molecular epidemiology of this virus is, however, poorly understood. In this study,...
China accounts for approximately 27% of global cancer deaths. However, to the authors' knowledge, the lasting effects of cancer and cancer treatments on patients have not been investigated in China. T...
Emergency medical service system (EMSS) in China is becoming more important. However, studies on mortality of emergency departments (EDs) patients in tertiary hospitals and on the trends in mortality ...
BASIC is a perspective, multicentre and large-scale registry focusing on of patients suffering a cardiac arrest in China. The aims of the study are to establish the monitoring sites coveri...
Prospective, multicenter, single-arm study, enroll 100 patients in no more than 10 sites across China, the primary endpoint is Technical success.
Trevo® Retriever Registry (China) is to assess real world performance of the SDA cleared Trevo Retriever intended to restore blood flow in the neurovasculature by removing thrombus in pat...
China PEACE Millions Persons Project is a national screening project for cardiovascular disease in China. This Project was approved by National Health and Family Planning Commission (NHFPC...
The purpose of this study is to assess clinical characteristics, treatment, and outcome of patients hospitalized with heart failure in China and compared those with other registries
Condensed Consolidated Balance Sheets
ECG, Bed monitor, Ultrasound Scanner , Dental , Fetal Doppler , Finger Oximeter , medical Cable, Parts , Visual Stethoscope ,medical equipments,SPO2
Park Place International provides a complete compliment of professional services and solutions for MEDITECH clients throughout North America. Our clients depend on us to keep their business-critical i...
China Business Solutions provides a one-stop consulting and research service to British companies doing or wishing to do business in China. With China's economy continuing to grow at 9% year on year, ...
We have published hundreds of Hutchison China MediTech Limited news stories on BioPortfolio along with dozens of Hutchison China MediTech Limited Clinical Trials and PubMed Articles about Hutchison China MediTech Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Hutchison China MediTech Limited Companies in our database. You can also find out about relevant Hutchison China MediTech Limited Drugs and Medications on this site too.